Reproductive issues including contraception, fertility, and pregnancy are important components of the comprehensive care of women with systemic lupus erythematosus (SLE). SLE pregnancies are complicated due to risk for maternal disease exacerbation and potential for fetal and neonatal complications. Pre-pregnancy assessment is important to identify patients with severe disease-related damage who should avoid pregnancy, counsel patients to conceive when disease has been stable and inactive on appropriate medications, and assess relevant risk factors including renal disease, antiphospholipid antibody, and anti-Ro/SS-A and anti-La/SS-B antibodies. With careful planning, monitoring, and care, most women with SLE can anticipate a successful pregnancy.


Article metrics loading...

Loading full text...

Full text loading...


Literature Cited

  1. Branch DW, Wong LF. 1.  2014. Normal pregnancy, pregnancy complications, and obstetric management. Contraception and Pregnancy in Patients with Rheumatic Disease LR Sammaritano, BL Bermas 31–62 New York: Springer [Google Scholar]
  2. Appenzeller S, Souza FHC, de Souza AWS. 2.  et al. 2011. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin. Arthritis Rheum. 41:517–23 [Google Scholar]
  3. Clowse ME, Jamison M, Myers E, James AH. 3.  2008. A national study of the complications of lupus in pregnancy. Am. J. Obstet. Gynecol. 199:2127.e1127.e6 [Google Scholar]
  4. Clowse ME. 4.  2007. Lupus activity in pregnancy. Rheum. Dis. Clin. N. Am. 33:2237–52 [Google Scholar]
  5. Chakravarty EF, Colon I, Langer ES. 5.  et al. 2005. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by SLE. Am. J. Obstet. Gynecol. 192:1897–1904 [Google Scholar]
  6. Buyon JP, Kim MY, Guerra MM. 6.  et al. 2015. Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann. Int. Med. 163:153–63 [Google Scholar]
  7. Flint J, Panchal S, Hurrell A. 7.  et al. 2016. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 551693–97
  8. Nalli C, Iodice A, Reggia R. 8.  et al. 2014. Long-term outcome of children of rheumatic disease patients. Contraception and Pregnancy in Patients with Rheumatic Disease LR Sammaritano, BL Bermas 289–303 New York: Springer [Google Scholar]
  9. Yasmeen S, Wilkins EE, Field NT. 9.  et al. 2001. Pregnancy outcomes in women with systemic lupus erythematosus. J. Matern. Fetal Med. 10:91–96 [Google Scholar]
  10. Jakobsen IM, Helmig RB, Stengaard-Pedersen K. 10.  2015. Maternal and foetal outcomes in pregnant systemic lupus erythematosus patients: an incident cohort from a stable referral population followed during 1990–2010. Scand. J. Rheum. 44:377–84 [Google Scholar]
  11. 11.  Deleted in proof
  12. Ritchie J, Smyth A, Tower C. 12.  et al. 2012. Maternal deaths in women with lupus nephritis: a review of published evidence. Lupus 21:534–41 [Google Scholar]
  13. Soh MC, Nelson-Piercy C, Dib F. 13.  et al. 2015. Brief report. Association between pregnancy outcomes and death from cardiovascular causes in parous women with systemic lupus erythematosus: a study using Swedish population registries. Arthritis Rheum 67:2376–82 [Google Scholar]
  14. Clowse ME, Magder LS, Witter F. 14.  et al. 2006. Early risk factors for pregnancy loss in lupus. Obstet. Gynecol. 107:293–99 [Google Scholar]
  15. Ruiz-Irastorza G, Lima F, Alves J. 15.  et al. 1996. Increased rate of lupus flare during pregnancy and the puerperieum: a prospective study of 78 pregnancies. Br. J. Rheumatol. 35:133–38 [Google Scholar]
  16. Borella E, Lojacono A, Gatto M. 16.  et al. 2014. Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunol. Res. 60:170–76 [Google Scholar]
  17. Saavedra MA, Sánchez A, Morales S. 17.  et al. 2015. Primigravida is associated with flare in women with systemic lupus erythematosus. Lupus 24:180–85 [Google Scholar]
  18. Tedeschi SK, Massarotti E, Guan H. 18.  et al. 2015. Specific systemic lupus erythematosus disease manifestations in the six months prior to conception are associated with similar disease manifestations during pregnancy. Lupus 24:1283–92 [Google Scholar]
  19. Smyth A, Oliveira GH, Lahr BD. 19.  et al. 2010. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin. J. Am. Soc. Nephrol. 5:2060–68 [Google Scholar]
  20. Chen TK, Gelber AC, Witter FR. 20.  et al. 2014. Renal biopsy in the management of lupus nephritis during pregnancy. Lupus 24:147–54 [Google Scholar]
  21. Miyakis S, Lockshin MD, Atsumi T. 21.  et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4:295–306 [Google Scholar]
  22. Lockshin MD, Kim M, Laskin CA. 22.  et al. 2012. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibody. Arthritis Rheum 64:2311–18 [Google Scholar]
  23. Ruffatti A, Tonello M, Visentin MS. 23.  et al. 2011. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre case–control study. Rheumatology 15:1684–89 [Google Scholar]
  24. De Carolis S, Botta A, Santucci S. 24.  et al. 2012. Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus 21:776–78 [Google Scholar]
  25. Clark CA, Spitzer KA, Laskin CA. 25.  2005. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. J. Rheumatol. 32:1709–12 [Google Scholar]
  26. Wallenius M, Salvesen , Daltveit AK. 26.  et al. 2015. Secular trends of pregnancies in women with inflammatory connective tissue disease. Acta Obstet. Gynecol. Scand. 94:1195–202 [Google Scholar]
  27. Ko HS, Ahn HY, Jang DG. 27.  et al. 2011. Pregnancy outcomes and appropriate timing of pregnancy in 183 pregnancies in Korean patients with SLE. Int. J. Med. Sci. 8:577–83 [Google Scholar]
  28. Moroni G, Ponticelli C. 28.  2003. The risk of pregnancy in patients with lupus nephritis. J. Nephrol. 16:161–67 [Google Scholar]
  29. Mankee A, Petri M, Magder LS. 29.  2015. Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss. Lupus Sci. Med. 2:1e000095 [Google Scholar]
  30. Clowse ME, Grotegut C. 30.  2016. Racial and ethnic disparities in the pregnancies of women with systemic lupus erythematosus. Arthritis Care Res 681567–72
  31. Wallenius M, Salvesen , Daltveit AK. 31.  et al. 2014. Systemic lupus erythematosus and outcomes in first and subsequent births based on data from a national birth registry. Arthritis Care Res 66:1718–24 [Google Scholar]
  32. Kim MY, Buyon JP, Guerra MM. 32.  et al. 2016. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am. J. Obstet. Gyn. 214:108.e1–108.e14 [Google Scholar]
  33. Wagner SJ, Craici I, Reed D. 33.  et al. 2009. Maternal and fetal outcomes in pregnant patients with active lupus nephritis. Lupus 8:342–47 [Google Scholar]
  34. Ruffatti A, Calligaro A, Hoxha A. 34.  et al. 2010. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res 62:302–9 [Google Scholar]
  35. Peixoto MV, de Carvalho JF, Rodrigues CE. 35.  2014. Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review. J. Immunol. Res. 2014672603
  36. Brito-Zerón P, Izmirly PM, Ramos-Casals M. 36.  et al. 2014. The clinical spectrum of autoimmune congenital heart block. Nat. Rev. Rheumatol. 11:301–12 [Google Scholar]
  37. Pisoni CN, Brucato A, Ruffatti A. 37.  et al. 2010. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum 62:1147–52 [Google Scholar]
  38. Friedman DM, Llanos C, Izmirly PM. 38.  et al. 2010. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 62:1138–46 [Google Scholar]
  39. Izmirly PM, Costedoat-Chalumeau N, Pisoni C. 39.  et al. 2012. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro associated cardiac manifestations of neonatal lupus. Circulation 126:76–82 [Google Scholar]
  40. Tunks RD, Clowse ME, Miller SG. 40.  et al. 2013. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am. J. Obstet. Gynecol. 208:164.e1–64.e7 [Google Scholar]
  41. Leroux M, Desveaux C, Parcevaux M. 41.  et al. 2015. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 24:1384–91 [Google Scholar]
  42. Clowse ME, Magder L, Witter F. 42.  et al. 2006. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54:3640–47 [Google Scholar]
  43. Cowchock FS, Reece EA, Balaban D. 43.  et al. 1992. Repeated fetal losses associated with antiphospholipid antibody: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am. J. Obstet. Gynecol. 166:1318–23 [Google Scholar]
  44. Mak A, Cheung MWL, Cheak AAC. 44.  et al. 2010. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 49:281–88 [Google Scholar]
  45. Ziakas PD, Pavlou M, Voulgarelis M. 45.  2010. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet. Gynecol. 115:1256–61 [Google Scholar]
  46. Branch DW, Peaceman AM, Druzin M. 46.  et al. 2000. A multicenter placebo-controlled pilot study of intravenous immunoglobulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am. J. Obstet. Gynecol. 182:122–27 [Google Scholar]
  47. Sciascia S, Hunt BJ, Talavera-Garcia E. 47.  et al. 2016. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am. J. Obstet. Gynecol. 214:273.e1–273.e8 [Google Scholar]
  48. Mekinian A, Lazzaroni MG, Kuzenko A. 48.  et al. 2015. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun. Rev. 14:498–502 [Google Scholar]
  49. Alijotas-Reig J. 49.  2013. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. Lupus 22:6–17 [Google Scholar]
  50. Salmon JE, Girardi G, Holers NM. 50.  2003. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 12:535–38 [Google Scholar]
  51. Gris JC, Bouvier S, Molinari N. 51.  et al. 2012. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 119:2624–32 [Google Scholar]
  52. Niebyl JR, Simpson JL. 52.  2012. Drugs and environmental agents in pregnancy and lactation: embryology, teratology, epidemiology. Obstetrics: Normal and Problem Pregnancies SG Gabbe, JR Niebyl, JL Simpson, MB Landon, HL Galan, ERM Jauniaux, DA Driscoll 141–65 Philadelphia: W.B. Saunders (Elsevier) [Google Scholar]
  53. Pall M, Friden BE, Brannstrom M. 53.  2001. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Hum. Reprod. 16:1323–28 [Google Scholar]
  54. Van Gelder MM, Roeleveld N, Nordeng H. 54.  2011. Exposure to nonsteroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. PLOS ONE 6:e22174 [Google Scholar]
  55. Edwards DR, Aldridge T, Baird DD. 55.  et al. 2012. Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet. Gynecol. 20:113–22 [Google Scholar]
  56. Blanford AT, Murphy BE. 56.  1977. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am. J. Obstet. Gynecol. 127:264–67 [Google Scholar]
  57. Hviid A, Mølgaard-Nielsen D. 57.  2011. Corticosteroid use during pregnancy and risk of orofacial clefts. Can. Med. Assoc. J. 183:796–804 [Google Scholar]
  58. Ost L, Wettrell G, Bjorkhem I. 58.  et al. 1985. Prednisolone excretion in human milk. J. Pediatr. 106:1008–11 [Google Scholar]
  59. Costedoat-Chalumeau N, Amoura Z, Houng DL. 59.  et al. 2005. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: review of the literature. Autoimmun. Rev. 4:111–15 [Google Scholar]
  60. Hart CW, Naunton RF. 60.  1964. The ototoxicity of chloroquine phosphate. Arch. Otolaryngol. 80:407–12 [Google Scholar]
  61. Osadchy A, Ratnapalan T, Koren G. 61.  2011. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J. Rheumatol. 38:2504–8 [Google Scholar]
  62. Motta M, Tincani A, Faden D. 62.  et al. 2005. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J. Perinatol. 25:86–89 [Google Scholar]
  63. Radomski JS, Ahlswede BA, Jarrell BE. 63.  et al. 1995. Outcomes of 500 pregnancies in 335 female kidney, liver, and heart transplant recipients. Transpl. Proc. 27:1089–90 [Google Scholar]
  64. Saavedra , Sánchez A, Morales S. 64.  et al. 2015. Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. Clin. Rheumatol. 34:1211–16 [Google Scholar]
  65. Gardner SJ, Gearry RB, Roberts RL. 65.  et al. 2006. Exposure to thiopurine drugs through breast milk is low based on metabolite concentration in mother-infant pairs. Br. J. Clin. Pharmacol. 62:453–56 [Google Scholar]
  66. Fischer-Betz R, Specker C, Brinks R. 66.  et al. 2013. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology 52:1070–76 [Google Scholar]
  67. Moretti ME, Sgro M, Johnson DW. 67.  et al. 2003. Cyclosporine excretion in breast milk. Transplant 75:2144–46 [Google Scholar]
  68. Kaintz A, Harabacz I, Cowlrick IS. 68.  et al. 2000. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation 70:1718–21 [Google Scholar]
  69. Webster P, Wardle A, Bramham K. 69.  et al. 2014. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 23:1192–96 [Google Scholar]
  70. Bramham K, Chusney G, Lee J. 70.  et al. 2013. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin. J. Am. Soc. Nephrol. 8:563–67 [Google Scholar]
  71. Feldcamp M, Carey JC. 71.  1993. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology 47:553–59 [Google Scholar]
  72. Clark AL, Gall SA. 72.  1997. Clinical uses of intravenous immunoglobulin in pregnancy. Am. J. Obstet. Gynecol. 176:241–53 [Google Scholar]
  73. Chakravarty EF, Murray ER, Kelman A. 73.  et al. 2011. Pregnancy outcomes after maternal exposure to rituximab. Blood 117:1499–506 [Google Scholar]
  74. Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA. 74.  1991. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet. Gynecol. 78:128–35 [Google Scholar]
  75. Schwartz EB, Manzi S. 75.  2008. Risk of unintended pregnancy among women with systemic lupus erythematosus. Arthritis Rheum 59:863–66 [Google Scholar]
  76. Yazdany J, Trupin L, Kaiser R. 76.  et al. 2011. Contraceptive counseling and use among women with systemic lupus: a gap in health care quality?. Arthritis Care Res 63:358–65 [Google Scholar]
  77. Stringer EM, Kaseba C, Levy J. 77.  et al. 2007. A randomized trial of the intrauterine device versus hormonal contraception in women who are infected with the human immunodeficiency virus. Am. J. Obstet. Gynecol. 197:144.e1–144.e8 [Google Scholar]
  78. Petri M, Kim MY, Kalunian KC. 78.  et al. 2005. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353:2550–58 [Google Scholar]
  79. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L. 79.  et al. 2005. A trial of contraceptive methods in women with systemic lupus erythematosus. N. Engl. J. Med. 353:2539–49 [Google Scholar]
  80. Stam-Slob MC, Lambalk CB. van de Ree MA. 80. , 2015. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ 351:h4847 doi: 10.1136/bmj.h4847 [Google Scholar]
  81. Mantha S, Karp R, Raghavan V. 81.  et al. 2012. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 345:e4944 doi: 10.1136/bmj.e4944 [Google Scholar]
  82. Boumpas DT, Austin HA, Vaughan EM. 82.  et al. 1993. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Int. Med. 119:366–69 [Google Scholar]

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error